argenx SE — 2017 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2017. The filing is an annual report, not a standalone fourth-quarter report. Financial statements are prepared under IFRS as issued by the IASB; amounts below are in euros unless noted.
Business context
argenx is a clinical-stage biotechnology company developing antibody-based treatments for severe autoimmune diseases and cancer. It had no approved products and generated no product-sale revenue. Revenue came from collaborations, milestones and research and development services.
Key financial metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | €36.4 million | €14.7 million |
| Other operating income | €4.8 million | €2.4 million |
| Research and development expense | €51.7 million | €31.6 million |
| Selling, general and administrative expense | €12.4 million | €7.0 million |
| Operating loss | €22.9 million | €21.4 million |
| Net loss | €28.1 million | €21.4 million |
| Basic and diluted loss per share | €1.14 | €1.14 |
| Cash and cash equivalents at year-end | €190.9 million | €89.9 million |
| Current financial assets | €168.9 million | €6.8 million |
| Total liabilities | €26.0 million | €42.4 million |
| Total equity | €344.9 million | €63.4 million |
Cash, cash equivalents and current financial assets totaled €359.8 million at year-end. Operating cash flow was an outflow of €36.5 million; investing cash flow was an outflow of €162.1 million, primarily reflecting purchases of financial assets; financing cash flow was an inflow of €305.4 million, mainly from U.S. public offerings. The company reported no material debt or off-balance-sheet arrangements. Management estimated existing resources would fund operations and capital needs through at least the next 12 months, subject to assumptions that may prove incorrect.
Changes versus prior year
- Revenue rose 148%, mainly due to recognition of collaboration upfront payments and increased milestone revenue; it remained collaboration-dependent rather than product-based.
- R&D expense increased 64%, reflecting higher clinical-trial, manufacturing and program costs. SG&A increased 78%, including higher personnel, public-company and office costs.
- Operating loss widened 7%, while net loss increased 31%. A €5.8 million foreign-exchange loss, mainly unrealized losses on U.S.-dollar cash and investments, and €0.6 million of tax expense contributed to the larger net loss.
- Cash and current financial assets rose substantially following the May and December 2017 U.S. offerings. Cash alone increased by €101.0 million, despite operating and investing outflows.
- Deferred revenue fell to €10.1 million from €30.2 million, reflecting recognition of previously received collaboration payments.
Outlook, commentary and risks
- ARGX-113: The company reported positive topline Phase 2 results in myasthenia gravis (MG): improvement on all four predefined efficacy measures and a favorable reported tolerability profile. In the 24-patient study, 75% of treated patients versus 25% on placebo achieved at least a two-point MG-ADL improvement sustained for six weeks (p=0.0391). Management planned to prepare for Phase 3 before the end of 2018, subject to FDA discussions. Phase 2 studies in ITP and pemphigus vulgaris were ongoing; topline ITP and interim PV results were expected in the second half of 2018.
- ARGX-110: Interim studies in CTCL and AML/high-risk MDS showed early activity, but remained small and ongoing. Management expected CTCL topline results in the second half of 2018 and planned to transition the AML/high-risk MDS combination study into Phase 2 during that period.
- The company expected continued losses and rising development expenses. It anticipated needing additional financing over time; unavailable or unfavorable funding could delay, reduce or terminate programs and may dilute shareholders.
- Key risks include clinical-trial failure or delay, safety and regulatory uncertainty, competition, patient-enrollment challenges, reliance on collaborators and third-party manufacturers, and dependence on intellectual-property protection. ARGX-110’s prior trials included serious adverse events and one investigator-attributed drug-related death in a heavily pre-treated patient; the company also disclosed a preclinical acute-death signal in an ARGX-110 variant model.
- Currency exposure is material: the company had no currency hedges and reported substantial U.S.-dollar exposure. It also relied on a limited number of manufacturing providers, including Lonza, and disclosed significant manufacturing commitments for ARGX-113 and ARGX-110.
- A Dutch tax ruling supported the restructuring treatment for an approximately €80 million IP-related indemnification, but a Belgian tax ruling remained pending. Failure to obtain the expected Belgian tax treatment could affect deductions and future taxes. The planned redomiciliation from the Netherlands to Belgium was not yet completed.
- Under IFRS 15, expected to be adopted in 2018, the company estimated an opening €2.7 million increase in deferred revenue and accumulated losses, principally because milestone revenue recognition would change.
Important facts for investors to verify
- Review final, audited clinical data and subsequent trial progress for ARGX-113, particularly the small Phase 2 MG study and plans for Phase 3; distinguish topline findings from confirmatory evidence.
- Check actual cash burn, investment liquidity and updated runway against management’s 12-month estimate, including the effects of clinical expansion and manufacturing commitments.
- Track collaboration receipts and milestone timing, and assess how dependent reported revenue remains on non-recurring payments and partner decisions.
- Confirm the outcome and tax implications of the Belgian ruling, restructuring and proposed redomiciliation; assess exposure to U.S.-dollar movements.
- Monitor clinical safety signals, manufacturing capacity and supplier concentration, especially as ARGX-113 advances toward later-stage development.
- Note that management concluded disclosure controls were effective at a reasonable-assurance level, but the filing did not include management’s ICFR assessment or an auditor attestation because of the applicable newly-public-company transition period.